Versant Venture Management, LLC Aprea Therapeutics, Inc. Transaction History

Versant Venture Management, LLC

$38.2 Million
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 11, 2022	SELL	$2.87 - $5.58 $3.62 Million - $7.03 Million	-1,259,662 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$4.73 - $8.15 $788,330 - $1.36 Million	-166,666 Reduced 11.68%	1,259,662 $6.42 Million
Q4 2020 Feb 16, 2021	SELL	$4.92 - $30.67 $2.11 Million - $13.1 Million	-427,901 Reduced 23.08%	1,426,328 $7.02 Million
Q2 2020 Jul 20, 2020	BUY	$25.47 - $39.69 $47.2 Million - $73.6 Million	1,854,229 New	1,854,229 $71.9 Billion

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,849
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Venture Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Versant Venture Management, LLC with notifications on news.